HLP003 Outperforms Placebo in Phase 3 MDD Trial
Key Clinical Summary
- HLP003, an investigational deuterated psilocin, reduced depressive symptoms compared with placebo in adults with major depressive disorder (MDD) who continued antidepressant treatment.
- At 6 weeks, depression rating scores declined by 19.5 points with HLP003 versus 11.9 points with placebo.
- Benefits remained statistically significant through 12 weeks, although 3 treatment-related serious adverse events occurred with HLP003.
HLP003 (deuterated psilocin), a novel serotonergic agonist under development for the adjunctive treatment of MDD in adults, met its primary and key secondary endpoints in the phase 3 APPROACH trial, announced manufacturer Helus Pharma. The company reported statistically significant improvements beginning on day 2 and continuing through the 12-week assessment.
HLP003 previously received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA).
Study Findings
The multicenter, randomized, double-blind, placebo-controlled trial included 222 adults with moderate to severe MDD (Montgomery-Åsberg Depression Rating Scale [MADRS] ≥ 24 at screening and baseline). Participants continued their stable antidepressant doses; 112 received HLP003 and 110 received placebo as adjunctive treatment.
At the primary endpoint of 6 weeks, least squares (LS) mean reductions on the MADRS were 19.5 points with HLP003 and 11.9 points with placebo (LS mean difference = -7.6 points, P < .0001, effect size = 0.653). The compound exhibited rapid onset, with a LS mean -16.1 points reduction on the MADRS as early as day 2, compared to -11.0 points with placebo (LS mean difference = -5.0 points, P = .0013, effect size = 0.438).
HLP003 also demonstrated a durable effect. At 12 weeks, MADRS reductions were 16.9 points with HLP003 and 9.9 points with placebo (LS mean difference = -7.0 points, P < 0.0001, effect size = 0.581).
At 6 weeks, response rates were 56.3% with HLP003 versus 28.2% with placebo, and remission rates were 50.9% versus 18.2%; (P < .0001 for both).
HLP003 “was generally well tolerated,” according to Helus Pharma. Most adverse events were mild to moderate, transient, and concentrated on dosing days. Three HLP003 treatment-related serious adverse events occurred, although the company reported no new safety signals.
Clinical Implications and Expert Commentary
The findings concern adding HLP003 to ongoing antidepressant treatment in adults with persistent depressive symptoms. Adjunctive treatment may enhance response to antidepressant therapy without requiring medication discontinuation or washout, as well as avoiding withdrawal symptoms.
“The results from the APPROACH study set a new benchmark for what may be achievable with adjunctive treatment in MDD,” said Roger S. McIntyre, MD, FRCPC, professor of psychiatry and pharmacology, University of Toronto. “The magnitude of benefit observed in this study is highly compelling and has the potential to redefine expectations among clinicians treating patients who continue to experience depressive symptoms while on an anti-depressant.”
APPROACH is the first study in the company’s phase 3 PARADIGM program. Results from the second pivotal trial, EMBRACE, are expected in the fourth quarter of 2027. The ongoing EXTEND study will assess longer-term safety, durability, and potential redosing with HLP003.
Reference


